Stockscreener 앱 받기
91.93
0.63%
-0.58
시간 외 거래:
91.93
Astrazeneca PLC 주식(AZN)의 최신 뉴스
My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN - MarketBeat
Zacks Research Raises Earnings Estimates for AstraZeneca - MarketBeat
Invest Outside the U.S. With These Top International ETFs - The Motley Fool
25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC - MarketBeat
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies - Yahoo Finance
Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel - Nasdaq
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN - MarketBeat
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Price Today - CoinMarketCap
AstraZeneca stock holds steady as mixed news and technicals limit major moves - Traders Union
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive financial news
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial - Clinical Trials Arena
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Sahm
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Sahm
Jacobio signs $1.9B deal with Astrazeneca for pan-KRAS inhibitor - BioWorld MedTech
AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2 - Bloomberg Law News
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
AstraZeneca reports Phase III trial of ceralasertib and Imfinzi did not meet main goal - Investing.com Nigeria
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial - Citeline News & Insights
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction - Investing.com
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals - GuruFocus
AstraZeneca (AZN) gains 10th FDA Breakthrough Therapy nod for Enhertu in HER2-positive early breast cancer - Stock Titan
AstraZeneca (LON:AZN) Insider Sells £40,083.12 in Stock - MarketBeat
FDA grants breakthrough therapy designation to AstraZeneca’s ENHERTU for HER2-positive early breast cancer - Investing.com UK
AstraZeneca PLCUpdate on LATIFY Phase III trial of ceralasertib - Research Tree
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial - marketscreener.com
Jacobio Strikes New Cancer Drug Deal with AstraZeneca - marketscreener.com
AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor - marketscreener.com
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView — Track All Markets
AstraZeneca (AZN) Advances Phase 3 Trial for Enhertu in Endometr - GuruFocus
AstraZeneca pulls Andexxa from US market after post-marketing fatalities - Pharmaceutical Technology
Astrazeneca Says Phase 3 Lung Cancer Trial Failed to Meet Primary Endpoint of Overall Survival - marketscreener.com
AstraZeneca, Daiichi Sankyo's Enhertu Gets Breakthrough Therapy Designation in the US - marketscreener.com
AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles - Vox Markets
AstraZeneca’s lung cancer trial fails to meet primary endpoint - Investing.com
AstraZeneca’s Enhertu gets FDA Breakthrough Therapy status for breast cancer - Investing.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Granted Breakthrough Therapy Status in US - marketscreener.com
AstraZeneca’s ceralasertib fails to meet primary endpoint in lung cancer trial - Investing.com Nigeria
AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial - Reuters
AstraZeneca's Lung Cancer Drug Misses Phase 3 Survival Goal - marketscreener.com
AstraZeneca says Latify phase III trial fails to meet primary endpoint in NSCLC - marketscreener.com
AstraZeneca's ceralasertib-Imfinzi drug combo misses survival target in lung cancer trial - marketscreener.com
AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor - Citeline News & Insights
Jacobio Pharma signs $2 billion license deal with AstraZeneca for cancer drug - Investing.com Nigeria
AstraZeneca PLC $AZN Position Boosted by Benson Investment Management Company Inc. - MarketBeat
Published on: 2025-12-20 18:56:48 - ulpravda.ru
AstraZeneca Unit Ducks Patent Fraud, Not Sham Suit Claims - Law360
Why global investors buy Precidian ETFs Trust AstraZeneca PLC stockRisk Management & Consistent Growth Stock Picks - Улправда
AstraZeneca PLC (AZN) Announces Approval of Saphnelo by the European Union - Insider Monkey
AstraZeneca (LON:AZN) Reaches New 1-Year HighHere's What Happened - MarketBeat
AstraZeneca (AZN) Among Companies Prepping Price Reductions - GuruFocus
AstraZeneca to Halt Andexxa Sales in US Over FDA Safety Concerns - marketscreener.com
AstraZeneca (AZN) Withdraws Andexxa Due to Safety Concerns - GuruFocus
AstraZeneca director gifts 5,735 shares to spouse in off-market transaction - Investing.com India
Voya Investment Management LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca (AZN) reports director Philip Broadley gifting 5,735 shares - Stock Titan
16,277 Shares in AstraZeneca PLC $AZN Bought by Montecito Bank & Trust - MarketBeat
AstraZeneca Discloses Director’s Gift of Shares to Spouse - TipRanks
Can AstraZeneca PLC Depositary Receipt stock double in next 5 yearsQuarterly Risk Review & Entry Point Strategy Guides - Улправда
자본화:
|
볼륨(24시간):